Poster Session (To be presented on March 5 from 6:45-8:45 p.m. ET)

P01 Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition. Kiyomi Mashima. Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

P02 Uncovering Tailored Therapies for Acute Myeloid Leukemia in Children with Down Syndrome. Billy Ta. McGill University, Montréal, Ontario, Canada.


P06 Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple Myeloma. Linda Baughn. Mayo Clinic, Eagan, Minnesota, United States.

P07 Identification of the unique preleukemic bone marrow niche in acute myeloid leukemia. Adrienne Dorrance. University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States.

P08 10x spatial transcriptomics of human AML core bone marrow biopsies reveals the complex remodeling of the non-hematopoietic stromal microenvironment post-treatment. Makayla Pardo. Brown University, Providence, Rhode Island, United States.

P09 Splicing and translation in chronic myeloid leukemia cells adapting to bone marrow microenvironment and chemotherapy. Paulina Podszywalow-Bartnicka. Nencki Institute of Experimental Biology and Yale University Department of Molecular Biophysics and Biochemistry, Warsaw, Poland.


P11 ARID1A mutations shape memory B-cell dynamics and confer sensitivity to SWI/SNF remodeling complex inhibition in lymphoma. Darko Barisic. Weill Cornell Medicine, New York, New York, United States.

P13 Genetic and epigenetic characterization of B-cell chronic lymphocytic leukemia with IG :: BCL3-translocation provides evidence for a distinct biological entity. Cosima Drewes. Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.

P14 Efficacy of FHD-286 monotherapy and combinations against Menin inhibitor sensitive and resistant AML cells. Warren Fiskus. UT MD Anderson Cancer Center, Houston, Texas, United States.

P15 Cross-species DNA methylation profiling of T and B cell populations in T-PLL and B-CLL compared to TCL1 transgenic mouse models. Selina Glaser. Ulm University, Ulm, Germany.
P16 CBFA2T3-GLIS2 fusion leads to a distinct DNA methylation enhancer landscape in pediatric acute myeloid leukemia. Samrat Roy Choudhury. University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.


P20 Anti-CD123 CAR NK cells and cam161533 Trispecific Killer Engager have synergistic activity against Acute Myeloid Leukemia. Yaya Chu. New York Medical College, White Plains, New York, United States.


P22 PVR (CD155) epigenetic status mediates adoptive cell therapy and anti-TIGIT response in Multiple Myeloma. Laura Martinez-Verbo. Josep Carreras Leukaemia Research Institute, Badalona, Spain.

P23 RHOA inactivation subverts IFN-y response and promotes antigen escape in CAR-T resistant diffuse large B-cell lymphoma. Austin Newsam. University of Miami Miller School of Medicine, Miami, Florida, United States.

P24 GABARAP deficiency drives resistance to immunogenic chemotherapy in multiple myeloma. Marcello Turi. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.

P25 Identification of biological components and novel clinical subsets of NPM1-mutated AML using an integrated, multi-omics approach. Salma Abdelbaky. The Ohio State University Wexner Medical Center, Columbus, Ohio, United States.

P26 Altered RNA Export Sensitizes to Nuclear Export Inhibition in SF3B1 Mutant MDS. Sana Chaudhry. University of Miami Miller School of Medicine, Miami, Florida, United States.


P28 Immunoproteasome inhibitors for the treatment of ALL. Alexei Kisselev. Auburn University, Auburn, Alabama, United States.

P30 Therapeutic activation of pre-B-cell receptor signaling in high-risk pediatric ALL: exploiting TCF3 and MYC-linked vulnerabilities. Isabelle Leo. Karolinska Institutet, Solna, Sweden.

P31 Graph-Based Deep Learning for Predicting Synergy in Multi-Drug Treatments for Leukemia. Archishma Marrapu. Thomas Jefferson High School for Science and Technology, Chantilly, Virginia, United States.

P33 Leveraging probabilistic causal disease models to understand molecular pathways and target resistance mechanisms in Multiple Myeloma with the CREBBP and EP300 bromodomain inhibitor, pocenbrodib. Allison Roder. Pathos AI, Salt Lake City, Utah, United States.

P34 Bayesian networks modeling identifies a reliance of TP53 mutant AML on NF kappa B signaling. Daniel Chang. University of Minnesota, Minneapolis, Minnesota, United States.

P35 High-grade B-cell lymphomas with 11q aberrations show a dark zone expression profile similar to Burkitt lymphoma but with additional extension towards intermediate germinal center B-cells. Emil Chteinberg. Universitätsklinikum Ulm, Ulm, Germany.

P36 BIOLOGY IN ACUTE LYMPHOBLASTIC LEUKEMIA FROM DIAGNOSIS TO FOLLOW-UP: A STUDY OF 48 CASES. Abou Koundio. Université Cheikh Anta Diop de Dakar, Dakar, Senegal.

P37 Decoding Cancer Dependency and Molecular Pathways of Long Noncoding RNAs with a Novel CRISPR-Cas13d Platform. Eugenio Morelli. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.

P38 Expanding the repertoire of physiologically relevant AML models to support new target drug discovery, compound screening, and predicting patient responses in clinical trials. Omid Tavana. AstraZeneca Oncology, Waltham, Massachusetts, United States.
